Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
Chengming Liu, Sufei Zheng, Zhanyu Wang, et al.
Cancer Communications (2022) Vol. 42, Iss. 9, pp. 828-847
Open Access | Times Cited: 78

Showing 26-50 of 78 citing articles:

Integration of graph neural networks and transcriptomics analysis identify key pathways and gene signature for immunotherapy response and prognosis of skin melanoma
Maodong Ye, Shuai Ren, Hong Luo, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Sotorasib-impaired degradation of NEU1 contributes to cardiac injury by inhibiting AKT signaling
Mengting Cheng, Wentong Wu, Xiu‐Qing Li, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
Man Wang, Lijie Zhu, Xiaoxu Yang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 12
Establishing the Role of Iridoids as Potential Kirsten Rat Sarcoma Viral Oncogene Homolog G12C Inhibitors Using Molecular Docking; Molecular Docking Simulation; Molecular Mechanics Poisson–Boltzmann Surface Area; Frontier Molecular Orbital Theory; Molecular Electrostatic Potential; and Absorption, Distribution, Metabolism, Excretion, and Toxicity Analysis
Mubarak A. Alamri, Abdullah S. Alawam, Mohammed Merae Alshahrani, et al.
Molecules (2023) Vol. 28, Iss. 13, pp. 5050-5050
Open Access | Times Cited: 11
A novel intranasal peptide vaccine inhibits non-small cell lung cancer with KRAS mutation
Su He Wang, Zhengyi Cao, Mohammad Farazuddin, et al.
Cancer Gene Therapy (2024)
Closed Access | Times Cited: 4
New perspectives on the potential of tetrandrine in the treatment of non-small cell lung cancer: bioinformatics, Mendelian randomization study and experimental investigation
Jihang Luo, Xiaocong Mo, Di Hu, et al.
Aging (2024)
Open Access | Times Cited: 4
Discovery of Novel and Highly Potent Dual PD-L1/Histone Deacetylase 6 Inhibitors with Favorable Pharmacokinetics for Cancer Immunotherapy
Zhihao Hu, Shuqing Li, Haiqi He, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Utilizing Nanoparticles to Overcome Anti-PD-1/PD-L1 Immunotherapy Resistance in Non-Small Cell Lung cancer: A Potential Strategy
Yuli Ge, Qiong Zhou, Fan Pan, et al.
International Journal of Nanomedicine (2025) Vol. Volume 20, pp. 2371-2394
Open Access
Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies
Parth Malik, Ruma Rani, Raghu Solanki, et al.
Exploration of Targeted Anti-tumor Therapy (2023), pp. 850-895
Open Access | Times Cited: 10
Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review
Chinmayee Dash, Dhruba Sonowal, Prachi Dhaka, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Serum sPD‐1 and sPD‐L1 as predictive biomarkers for HBsAg clearance in HBeAg‐negative CHB patients undergoing IFN‐based therapy
Xiyao Chen, Boxiang Zhang, Xin Song, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 5, pp. 593-603
Closed Access | Times Cited: 3
The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer
William J. McDaid, L Wilson, Helen Adderley, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 3
Mesenchymal Stem Cell-Derived Extracellular Vesicles in Cancer Therapy Resistance: from Biology to Clinical Opportunity
Chan Shan, Yan Liang, Kun Wang, et al.
International Journal of Biological Sciences (2023) Vol. 20, Iss. 1, pp. 347-366
Open Access | Times Cited: 8
Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors
Joshua Friedman, Tomi Jun, Omid Rashidipour, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 6, pp. 1893-1901
Closed Access | Times Cited: 7
Nanomaterials-based precision sonodynamic therapy enhancing immune checkpoint blockade: A promising strategy targeting solid tumor
Xinlun Dai, Yangyang Du, Yumei Li, et al.
Materials Today Bio (2023) Vol. 23, pp. 100796-100796
Open Access | Times Cited: 7
Anti-Tumor Potential of Post-Translational Modifications of PD-1
Xiaoming Xi, Wuli Zhao
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 3, pp. 2119-2132
Open Access | Times Cited: 2
Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study
Xiaoqi Yan, Luqing Zhao, Fei Wu, et al.
Journal of Thoracic Disease (2024) Vol. 16, Iss. 3, pp. 1787-1803
Open Access | Times Cited: 2
Efficacy of immune checkpoint inhibitors in advanced non‐small cell lung cancer patients with KRAS mutations: A network meta‐analysis
Lin Zhang, Wei Chen, Hongtao Wei, et al.
The Clinical Respiratory Journal (2024) Vol. 18, Iss. 4
Open Access | Times Cited: 2
Loss of STK11 Suppresses Lipid Metabolism and Attenuates KRAS-Induced Immunogenicity in Patients with Non-Small Cell Lung Cancer
Daniel R. Principe, Mary Pasquinelli, Ryan H. Nguyen, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 8, pp. 2282-2294
Open Access | Times Cited: 2
KRAS mutations in endometrial cancers: Possible prognostic and treatment implications
Karolina A. Kilowski, Martin Dietrich, Joanne Xiu, et al.
Gynecologic Oncology (2024) Vol. 191, pp. 299-306
Open Access | Times Cited: 2
Examination of the Functional Relationship between PD-L1 DNA Methylation and mRNA Expression in Non-Small-Cell Lung Cancer
Tina Vilsbøll, Nina Dybdal, Tina Fuglsang Daugaard, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1909-1909
Open Access | Times Cited: 6
Cancer Cell-Intrinsic Alterations Associated with an Immunosuppressive Tumor Microenvironment and Resistance to Immunotherapy in Lung Cancer
Nerea Otegui, Maeva Houry, Imanol Arozarena, et al.
Cancers (2023) Vol. 15, Iss. 12, pp. 3076-3076
Open Access | Times Cited: 6
Clinical outcomes of KRAS-mutant non-small cell lung cancer under untargeted therapeutic regimes in the real world: a retrospective observational study
Mingming Wang, Yong Zhang, Shuo Wu, et al.
Translational Lung Cancer Research (2023) Vol. 12, Iss. 10, pp. 2030-2039
Open Access | Times Cited: 6
PCK2 inhibits lung adenocarcinoma tumor cell immune escape through oxidative stress-induced senescence as a potential therapeutic target
Mingming Tang, Jianjun Sun, Zhigang Cai
Journal of Thoracic Disease (2023) Vol. 15, Iss. 5, pp. 2601-2615
Open Access | Times Cited: 5
The emerging role and mechanism of HMGA2 in breast cancer
Qing Ma, Sisi Ye, Hong Liu, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 5
Open Access | Times Cited: 1

Scroll to top